PharmaCyte Biotech, Inc.
PMCB
$1.19
$0.043.48%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 16.76M | 20.84M | 32.64M | 50.18M | 61.21M |
| Total Receivables | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 207.40K | 493.20K | 240.20K | 259.80K | 297.80K |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 16.96M | 21.33M | 32.88M | 50.44M | 61.51M |
|
|
|||||
| Total Current Assets | 16.96M | 21.33M | 32.88M | 50.44M | 61.51M |
| Net Property, Plant & Equipment | -- | -- | -- | -- | -- |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | 1.55M | 1.55M | 1.55M | 1.55M | 3.55M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 6.69M | 7.36M | 6.65M | 7.91M | 4.73M |
| Total Assets | 43.83M | 55.10M | 70.19M | 59.90M | 71.36M |
|
|
|||||
| Total Accounts Payable | 484.90K | 348.60K | 554.00K | 389.40K | 484.20K |
| Total Accrued Expenses | 709.40K | 707.20K | 684.10K | 735.20K | 774.40K |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Liabilities | -- | 3.72M | 6.23M | 463.40K | 991.00K |
| Total Other Current Liabilities | -- | 3.72M | 6.23M | 463.40K | 991.00K |
| Total Current Liabilities | 1.19M | 4.78M | 7.47M | 1.59M | 2.25M |
|
|
|||||
| Total Current Liabilities | 1.19M | 4.78M | 7.47M | 1.59M | 2.25M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 2.38M | 6.87M | 9.68M | 12.97M | 14.93M |
| Total Liabilities | 3.58M | 11.65M | 17.15M | 14.56M | 17.18M |
|
|
|||||
| Common Stock & APIC | 181.43M | 181.36M | 182.73M | 185.34M | 189.22M |
| Retained Earnings | -96.72M | -93.67M | -92.20M | -115.63M | -116.97M |
| Treasury Stock & Other | -44.46M | -44.23M | -42.81M | -42.06M | -40.88M |
| Total Common Equity | 40.25M | 43.45M | 47.71M | 27.65M | 31.38M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | 5.83M | 5.29M |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | 5.33M | 11.87M | 17.52M |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | 5.33M | 17.70M | 22.81M |
|
|
|||||
| Total Common Equity | 40.25M | 43.45M | 47.71M | 27.65M | 31.38M |
| Total Preferred Equity | -- | -- | 5.33M | 17.70M | 22.81M |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 40.25M | 43.45M | 53.04M | 45.35M | 54.18M |
|
|
|||||